Corvus Pharmaceuticals, Inc. (CRVS) — 10-Q Filings

10-Q Filings (6)

• Corvus Narrows Losses, Boosts Marketable Securities Amid Going Concern Doubts — Nov 4, 2025 Risk: high
  Corvus Pharmaceuticals, Inc. reported a net loss of $10.157 million for the three months ended September 30, 2025, a significant improvement from the $40.217 mi
• Corvus Narrows Q2 Loss Amid R&D Cuts, Seeks Mupadolimab Partner — Aug 7, 2025 Risk: high
  Corvus Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, reflecting its clinic
• Corvus Pharma Q1 2025: Assets $68.17M, Liabilities $67.90M — May 8, 2025 Risk: medium
  Corvus Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $68,169,461 and total liabilities of $67,
• Corvus Pharma Reports Q3 2024 Results, Equity Offering — Nov 12, 2024 Risk: medium
  Corvus Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant financial activities, including a registe
• Corvus Pharma Reports Q2 2024 Results, Completes Offering — Aug 6, 2024 Risk: medium
  Corvus Pharmaceuticals, Inc. filed a 10-Q for the period ending June 30, 2024. The company reported total assets of $59.7 million and total liabilities of $4.7
• Corvus Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk:
  Corvus Pharmaceuticals, Inc. (CRVS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Corvus Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX